Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | NQO2 | P16083 | 4/20 | 0.46 |
| ▸ | RAB9A | P51151 | 3/20 | 0.44 |
| ▸ | CASR | P41180 | 1/20 | 0.44 |
| ▸ | PDE10A | Q9Y233 | 3/20 | 0.43 |
| ▸ | PDE2A | O00408 | 1/20 | 0.43 |
| ▸ | PDE6D | O43924 | 1/20 | 0.43 |
| ▸ | PDE6A | P16499 | 1/20 | 0.43 |
| ▸ | PDE6G | P18545 | 1/20 | 0.43 |
| ▸ | PDE4A | P27815 | 1/20 | 0.43 |
| ▸ | PDE6B | P35913 | 1/20 | 0.43 |
| ▸ | PDE6C | P51160 | 1/20 | 0.43 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.43 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.43 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.43 |
| ▸ | PDE6H | Q13956 | 1/20 | 0.43 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6652836 | 0.82 | NQO2 (0.49) | TLR8ALDH1A1SMN1; SMN2NQO2RAB9A | |
| SCHEMBL7707554 | 0.82 | TLR8 (0.48) | TLR8SMN1; SMN2NQO2RAB9ACASR | |
| SCHEMBL3860530 | 0.81 | TLR8 (0.61) | TLR8ALDH1A1SMN1; SMN2NQO2RAB9A | |
| SCHEMBL1161432 | 0.80 | RAB9A (0.50) | TLR8ALDH1A1NQO2RAB9ACASR | |
| SCHEMBL9272589 | 0.80 | CASR (0.43) | TLR8ALDH1A1SMN1; SMN2NQO2CASR | |
| SCHEMBL11218463 | 0.78 | CXCR3 (0.46) | TLR8ALDH1A1NQO2RAB9APDE10A | |
| SCHEMBL14685303 | 0.77 | RAB9A (0.57) | TLR8SMN1; SMN2NQO2RAB9ACASR | |
| SCHEMBL6950074 | 0.77 | TLR8 (0.44) | TLR8ALDH1A1SMN1; SMN2NQO2RAB9A | |
| SCHEMBL14685298 | 0.76 | PDE10A (0.53) | TLR8SMN1; SMN2RAB9ACASRPDE10A | |
| SCHEMBL6953638 | 0.76 | CXCR3 (0.56) | TLR8ALDH1A1SMN1; SMN2NQO2RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2400961-B1 | MEDICINE COMBINATIONS CONTAINING PDE4 INHIBITORS AND NSAIDS | BOEHRINGER INGELHEIM INT (DE) | 2017-11-22 | — | — | EP | disclosed |
| EP-2400961-B1 | MEDICINE COMBINATIONS CONTAINING PDE4 INHIBITORS AND NSAIDS | BOEHRINGER INGELHEIM INT (DE) | 2017-11-22 | — | — | EP | disclosed |
| EP-2205609-B1 | HETEROCYCLE SUBSTITUTED PIPERAZINO DIHYDROTHIENO PYRIMIDINES | BOEHRINGER INGELHEIM INT (DE) | 2017-03-29 | — | — | EP | disclosed |
| EP-2205609-B1 | HETEROCYCLE SUBSTITUTED PIPERAZINO DIHYDROTHIENO PYRIMIDINES | BOEHRINGER INGELHEIM INT (DE) | 2017-03-29 | — | — | EP | disclosed |
| US-9115142-B2 | Heterocycle-substituted piperazino-dihydrothienopyrimidines | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-08-25 | — | — | US | disclosed |
| US-9115142-B2 | Heterocycle-substituted piperazino-dihydrothienopyrimidines | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-08-25 | — | — | US | disclosed |
| US-9115142-B2 | Heterocycle-substituted piperazino-dihydrothienopyrimidines | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-08-25 | — | — | US | disclosed |
| US-8877758-B2 | Combinations of medicaments, containing PDE4-inhibitors and EP4-receptor-antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-11-04 | — | — | US | disclosed |
| US-8877758-B2 | Combinations of medicaments, containing PDE4-inhibitors and EP4-receptor-antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-11-04 | — | — | US | disclosed |
| US-8877758-B2 | Combinations of medicaments, containing PDE4-inhibitors and EP4-receptor-antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-11-04 | — | — | US | disclosed |
| WO-2011124524-A1 | COMBINATIONS OF MEDICAMENTS, CONTAINING PDE4 INHIBITORS AND EP4 RECEPTOR ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-10-13 | — | — | WO | disclosed |
| WO-2011124524-A1 | COMBINATIONS OF MEDICAMENTS, CONTAINING PDE4 INHIBITORS AND EP4 RECEPTOR ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-10-13 | — | — | WO | disclosed |
| US-20100305102-A1 | HETEROCYCLE-SUBSTITUTED PIPERAZINO-DIHYDROTHIENOPYRIMIDINES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-12-02 | — | — | US | disclosed |
| US-20100305102-A1 | HETEROCYCLE-SUBSTITUTED PIPERAZINO-DIHYDROTHIENOPYRIMIDINES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-12-02 | — | — | US | disclosed |
| US-20100305102-A1 | HETEROCYCLE-SUBSTITUTED PIPERAZINO-DIHYDROTHIENOPYRIMIDINES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-12-02 | — | — | US | disclosed |
| WO-2010097332-A1 | DRUG COMBINATIONS CONTAINING PDE4 INHIBITORS AND NSAIDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-09-02 | — | — | WO | disclosed |
| WO-2010097332-A1 | DRUG COMBINATIONS CONTAINING PDE4 INHIBITORS AND NSAIDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-09-02 | — | — | WO | disclosed |
| EP-2205609-A2 | HETEROCYCLE-SUBSTITUTED PIPERAZINO-DIHYDROTHIENOPYRIMIDINES | Boehringer Ingelheim International GmbH (DE) | 2010-07-14 | — | — | EP | disclosed |
| WO-2009050242-A2 | HETEROCYCLE-SUBSTITUTED PIPERAZINO-DIHYDROTHIENOPYRIMIDINES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-04-23 | — | — | WO | disclosed |
| WO-2009050242-A2 | HETEROCYCLE-SUBSTITUTED PIPERAZINO-DIHYDROTHIENOPYRIMIDINES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-04-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100305102-A1 | HETEROCYCLE-SUBSTITUTED PIPERAZINO-DIHYDROTHIENOPYRIMIDINES | SULT2A1, DPYD, HRH2 | TLR8 593/4885ALDH1A1 440/4885SMN1; SMN2 486/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.